Floatz logo

Solu-Cortef

Recurrent Childhood Acute Myeloid Leukemia

Children's Oncology GroupPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Recurrent Childhood Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →